Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access

Original Research

Retrospective analyses of clinical and laboratory features of 646 patients with prolactinoma in Turkey

Berçem Ayçiçek Doğan, Müyesser Sayki Arslan, Serhat Işik, Esra Tutal, Dilek Berker, Melia Karaköse, Serdar Güler, Tuncay Delibaşi.

Background: Prolactinomas are the most frequently occurring pituitary adenomas and consist of nearly 40% of all pituitary adenomas. Their prevalence varies from approximately 60 to 100 inhabitants per million.

Objectives: This study aimed to determine demographic and clinical features of patients with prolactinoma. In addition, it targeted to determine success percentage of medical therapy and frequency of dopamine agonist (DA) resistance.

Materials and Methods: Records of 646 patients who were admitted to Endocrinology and Metabolism Disease department of two hospitals in Turkey between 2007 and 2014 were evaluated retrospectively. Data of the study were obtained from file records for 53% patients and ICD-10 diagnosis code of electronic database of the hospital in 47% of patients.

Results: Of patients who received medical therapy, 91.7% (n = 394) had received cabergoline (CAB) and 8.6% (n = 55) had received bromocriptine (BMC). While normalization rate of prolactin was 92.7% with medical therapy, size of the adenoma completely regressed in 59.7% patients. Size of the adenoma decreased more than 50% in 56% patients. Resistance was detected against DA drugs in 6.9% patients. DA resistance found in 3.9% of patients with microprolactinoma and 27% of patients with macroprolactinoma.

Conclusion: Success percentage of CAB therapy was found greater than BMC therapy in patients with microprolactinoma, which was in line with the literature. And, frequency of DA resistance was found to be lower in patients with microprolactinoma and greater in patients with macroprolactinoma than that reported in the literature.

Key words: Dopamine agonist resistance, efficacy of dopamine agonist treatment, Prolactinoma

Share this Article

American Journal of Research in Medical Sciences


BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.